



MEMBERSHIP
MOVES
MEDICINE™

Telemedicine and Mobile Apps Accessing Birth Control Without Stepping Foot in a Clinic


Brandi Ring, MD, FAWM

Dr. Ring

- Dr. Brandi Ring, MD, FAWM, is originally from Westminster, CO. After graduating from CU Boulder, she completed her Master's degree and then Medical School at Boston University School of Medicine. She developed a deep passion for serving the underserved and developing health policy and became an advocate for patients and physicians through her work with the American Medical Association. She completed her residency in OB/GYN at York Hospital in York, PA. Dr. Ring actively advocates for her patients, her colleagues and her specialty. She can frequently be found in state and national capitols discussing health policy. Her specialty interests include high-risk and low-risk pregnancy, family planning, wilderness medicine, LGBT care, well-women care and preventative health.
- She is the President of the Aurora-Adams County Medical Society, serves on the Colorado Medical Society board and is honored to be the CMS Medical Student Component Board Liaison. She is also active in her specialty society, the American College of Obstetricians and Gynecologists where she serves on the executive

Socrative

- <https://b.socrative.com/login/student/>



Disclosures

- Private Practice OB/GYN
- Board of ACOG

Contraceptives



Risk of Pregnancy in the US

- 61 Million women (age 15-44)¹
 - 70% sexually active with male partner and at risk for pregnancy
- In one year – 85% of couples would get pregnant with no method³
- The average desired family size is 2 children⁴

So on average women
need some form of
contraception for ~34
years!!

So who uses Contraception?

- 99% of women have used some contraceptive in their life⁵
- At any given time 60% are currently using some method.⁶
 - 10% are not (and are not trying to get pregnant)
 - Increased in younger women (18%) vs older women (9%)²
- Varies by ethnicity
 - 83% of Black women
 - 91% of Hispanic women
 - 90% of Asian women
 - 91% of White women



Who uses contraception?

- Varies by Income²
- 92% if at 300% of Federal Poverty Level
- 89% if below 150% of FPL
- Varies by Religion⁷
 - 89% Catholics
 - 90% Protestants
- Varies by Marital Status²
 - 93% Married
 - 90% Unmarried / Cohabiting
 - 83% Never married

How well does contraception work?

- 68% consistent use = 5% unintended pregnancies
- 18% inconsistent use = 41% of unintended pregnancies,
- 14% who do not use contraceptives at all or have a gap in use of at least one month account for 54% of unintended pregnancies.⁴

CONTRACEPTIVE EFFECTIVENESS

Proportion of women who will become pregnant over one year of use, by method

METHOD	Perfect use	Typical use
Implant	0.05	0.05
Vasectomy (male sterilization)	0.10	0.15
Intrauterine device (IUD)		
Levonorgestrel-releasing	0.2	0.2
Copper-T	0.6	0.8
Tubal (female) sterilization	0.5	0.5
Injectable	0.2	4
Pill	0.3	7
Vaginal ring	0.3	9
Patch	0.3	9
Diaphragm	6	12
Sponge**	9/20	12/24
Male condom	2	13
Female condom	5	21
Withdrawal	4	20
Fertility awareness methods***	0.4-5	24
Spermicides	18	28
Emergency contraception	*	*
No method	85	85

*The effectiveness of emergency contraception is not measured on a one-year basis like other methods. It is estimated to reduce the incidence of pregnancy by approximately 90% when used to prevent pregnancy after one instance of unprotected sex. **For sponge, first figure is for women who have not given birth and second is for women who have given birth.


***Includes cervical mucus methods, body temperature methods and periodic abstinence.

NOTES: u=unavailable. "Perfect use" denotes effectiveness among couples who use the method both consistently and correctly; "typical use" refers to effectiveness experienced among all couples who use the method (including inconsistent and incorrect use).

www.guttmacher.org

What Contraceptive do they use?

- 72% use non-permanent method
- 29% use permanent method
 - 22% Female
 - 7% Male



- **Pill – 25.3%**
- **Condoms – 14.6%**
- **IUD – 11.8%**
- **Withdrawal – 8.1%**
- **Depo Provera – 3.9%**
- **Implant 2.6%**
- **Ring - 2.4%**
- **Patch – 0.2%**
- **Plan B / EllaOne– 0.2%**


**Most effective method used in the past month
by U.S. women, 2014**

METHOD	No. of women	% of women aged 15–44	% of women at risk of unintended pregnancy	% of contraceptive users
Pill	9,572,477	15.6	22.7	25.3
Tubal (female) sterilization	8,225,149	13.4	19.5	21.8
Male condom	5,496,905	8.9	13.0	14.6
IUD	4,452,344	7.2	10.6	11.8
Vasectomy (male sterilization)	2,441,043	4.0	5.8	6.5
Withdrawal	3,042,724	5.0	7.2	8.1
Injectable	1,481,902	2.4	3.5	3.9
Vaginal ring	905,896	1.5	2.1	2.4
Fertility awareness-based methods	832,216	1.3	2.0	2.2
Implant	965,539	1.6	2.3	2.6
Patch	69,106	0.1	0.2	0.2
Emergency contraception	69,967	0.1	0.2	0.2
Other methods*	234,959	0.4	0.6	0.6
No method, at risk of unintended pregnancy	4,408,474	7.2	10.5	na
No method, not at risk	19,302,067	31.4	na	na
Total	61,491,766	100.0	100.0	100.0

[illegible]

Who uses the pill?

- 4 of every 5 women ⁵
- Most widely used by
 - white women
 - Women in teens and 20's
 - never-married and cohabiting women
 - childless women
 - college graduates.²



How do women get Birth Control?

- Traditional
 - Visit physician – get prescription – fill it at pharmacy every month
- Barriers
 - Physician – Have one, See one, Willing to prescribe – REPEAT EVERY YEAR
 - Pharmacy – Get prescription there, Get to the pharmacy to pick up, Afford to pay – REPEAT EVERY MONTH
- So is there a better way?
 - How can we reduce barriers



should be as easy as



Why?

Study participants cited:

- cost barriers or lack of insurance (14%)
- challenges obtaining an appointment or getting to a clinic (13%)
- the clinician requiring a clinic visit, examination, or Pap test (13%)
- not having a regular doctor or clinic (10%)
- difficulty accessing a pharmacy (4%)



Over The Counter Access

- Endorsed by ACOG – Committee Opinion²⁸
- Regulatory Change by the FDA
- ameliorate some of the aforementioned barriers
- 70% of the world already does this²⁹
- But recommendations have not translated into regulatory changes
 - SO – FOR now telemedicine of birth control is the middle ground option available




History of Birth Control Outside the Office

- 1999 – First online pharmacy
- 2005 – First ability to fill out questionnaire online and get birth control
- 2018 - 8 online companies focused on birth control alone
 - One has over 200,000 users
- But even if all 8 companies had 200,000 users –
 - Only 1.6 million women (of the ~60.3 million that need it or 2.7% of women)

Why?

- Ease of Access
 - 24/7 access instead of 9a-5p
 - Open holidays / weekends
 - Shipped to home – no travel
 - Covered through insurance or very low cost (as low as \$21 for a 3 month supply)



Availability: 24 hours



Cost: Varies



Service Areas: Worldwide



Insurance Accepted:
Medicare, Medicaid, most private
insurance plans

Questions to Ask

- Do women need to see a physician to get birth control?
- Do they need an exam? Testing?
- Do they need to be seen again to get refills?
- How do we still keep women safe?

A DOCTOR'S OFFICE IN YOUR POCKET




Safety



- Concern that increased access may increase complications
 - Two studies have evaluated the safety of self-administered checklists to screen for contraindications.[12,13](#)
 - As effective, if not more effective, than physician or nurse practitioner screening
 - The only exception may be hypertension
- Direct-To-Consumer
 - Safety Guidelines
 - 2019 study showed that all online companies were providing appropriate screening and provision of contraceptives

Concerns

- No physical exam
 - No vital signs
 - Can we request patients check BP and enter prior to ordering
- Limited Options
 - Can only prescribe limited options – “formulary restrictions”
 - Unable to do LARCs or those requiring in-person administration
 - Full counseling of all options available – not just available through site



Off Label Use

- Multiple other reasons we prescribe birth control
 - dysmenorrhea, menorrhagia, endometriosis, menstrual-related migraines, acne, uterine leiomyomas, and polycystic ovarian syndrome
- Legal for physicians to prescribe for off label use
- Illegal to advertise/promote for off label use



Proposed Guidelines³²

- 1) Direct-to-consumer companies should offer first-line, standard-of-care treatment for appropriate indications. They may also offer second- or third-line treatments for patients with contraindications or when standard-of-care treatment fails, as long as it is safe and appropriate without an in-person visit or physical examination.
- 2) Direct-to-consumer companies should have a licensed health care provider with prescribing privileges review individual prescriptions.
- 3) Direct-to-consumer companies should have appropriate systems in place to screen people for relative and absolute contraindications, taking care to ensure these are appropriate for many levels of health and general literacy. Furthermore, we encourage direct-to-consumer companies to use validated screening questionnaires to ensure adequate screening.
- 4) Direct-to-consumer companies should have clear disclosures about the possible side effects of medications and have systems in place to monitor patients for these side effects.
- 5) Direct-to-consumer companies should use language that avoids medical jargon and is readily understandable for patients accessing materials online, bearing in mind potential limited health literacy and language barriers.
- 6) In the event of medical complications resulting from online therapy, there should be systems in place to refer patients for appropriate in-person routine or emergent care as needed.
- 7) Direct-to-consumer companies should not advertise the use of prescription medication for off-label uses and should prescribe these only if they are deemed safe by a physician or health care provider with prescribing privileges.
- 8) Direct-to-consumer companies should have an obstetrician-gynecologist, certified nurse-midwife, certified midwife, or similarly licensed women's health care provider in their clinical team if providing hormonal treatment to women.

Guidelines³²

- 1) Offer first-line therapy and second- or third-line treatments contraindications or when treatment fails when safe and appropriate
- 2) Licensed health care provider with prescribing privileges review prescriptions
- 3) Screen for relative and absolute contraindications, use validated screening questionnaires
- 4) Clear disclosures of side effects with systems to monitor for side effects
- 5) Use readable language online
- 6) systems to refer for appropriate in-person routine or emergent care
- 7) should not advertise the use of prescription medication for off-label use and only if safe
- 8) should have a licensed women's health care provider if providing hormonal treatment

How to . . .³³

- *28H – Twentyeight Health*
- *HeyDoctor*
- *Nurx*
- *Pandia Health*
- *The Pill Club*
- *PillPack*
- *Planned Parenthood Direct*
- *PRJKT RUBY*
- *Simple Health*
- *Hers*

Google

Birth Control + Online

Enter Info online

Screening Survey

Wait for approval

Delivered to you

How can you help you patients?

- Willing to talk about it
- Willing to write prescriptions to access online delivery service
- Willing to write for 90 day supply, full year refills
- Willing to refill without visits, exams, tests
- Explain reasons to make appointments / annual exam
- Explain things to watch for / side effects / problems
- Counsel on LARC options



How to stay out of trouble

- Know the laws in your state
 - Age laws for consent to sexual health services
 - Confidentiality laws
- Know the FDA laws regarding promotion of drugs
 - Monitor site advertising
- Give patients accurate information, precautions on side effects, discuss risks
 - If only in written form – make sure it is readable, comprehensive

New Innovation Everyday

- Onsite Telemedicine
- Pharmacist Standing Prescriptions
- Over The Counter Access



Questions?





MEMBERSHIP
MOVES
MEDICINE™

Resources

Guttmacher - <https://www.guttmacher.org/fact-sheet/contraceptive-use-united-states>

1. Daniels K et al., Current contraceptive use and variation by selected characteristics among women aged 15–44: United States, 2011–2013, *National Health Statistics Reports*, 2015, No. 86, <https://www.cdc.gov/nchs/data/nhsr/nhsr086.pdf>.
2. Jones J, Mosher W and Daniels K, Current contraceptive use in the United States, 2006–2010, and changes in patterns of use since 1995, *National Health Statistics Reports*, 2012, No. 60, <https://www.cdc.gov/nchs/data/nhsr/nhsr060.pdf>.
3. Hatcher RA et al., eds., *Contraceptive Technology*, 20th revised ed., New York: Ardent Media, 2011.
4. Sonfield A, Hasstedt K and Gold RB, *Moving Forward: Family Planning in the Era of Health Reform*, New York: Guttmacher Institute, 2014, <https://www.guttmacher.org/report/moving-forward-family-planning-era-health-reform>.
5. Daniels K, Mosher WD and Jones J, Contraceptive methods women have ever used: United States, 1982–2010, *National Health Statistics Reports*, 2013, No. 62, <https://pdfs.semanticscholar.org/1cfe/9a5b9a1fd9c75acee82612c4b38294ebf937.pdf>.
6. Kavanaugh ML and Jerman J, Contraceptive method use in the United States: trends and characteristics between 2008 and 2014, *Contraception*, 2018, 97(1):14–21, doi:10.1016/j.contraception.2017.10.003.
7. Jones RK and Dreweke J, *Countering Conventional Wisdom: New Evidence on Religion and Contraceptive Use*, New York: Guttmacher Institute, 2011, <https://www.guttmacher.org/report/countering-conventional-wisdom-new-evidence-religion-and-contraceptive-use>.
8. Daniels K, Daugherty JD and Jones J, Current contraceptive status among women aged 15–44: United States, 2011–2013, *NCHS Data Brief*, Hyattsville, MD: National Center for Health Statistics (NCHS), 2014, No. 173, <https://www.cdc.gov/nchs/data/databriefs/db173.pdf>.
9. Mosher WD and Jones J, Use of contraception in the United States: 1982–2008, *Vital and Health Statistics*, Hyattsville, MD, 2010, Series 23, No. 29, https://www.cdc.gov/nchs/data/series/sr_23/sr23_029.pdf.
10. Kavanaugh ML, Jerman J and Finer LB, Changes in use of long-acting reversible contraceptive methods among U.S. women, 2009–2012, *Obstetrics & Gynecology*, 2015, 126(5):917–927, doi:10.1097/AOG.0000000000001094.
11. Finer LB, Jerman J and Kavanaugh ML, Changes in use of long-acting contraceptive methods in the United States, 2007–2009, *Fertility and Sterility*, 2012, 98(4):893–897, doi:10.1016/j.fertnstert.2012.06.027.
12. Sonfield A, Why family planning policy and practice must guarantee a true choice of contraceptive methods, *Guttmacher Policy Review*, 2017, 20:103–107.
13. Sharma V et al., Vasectomy demographics and postvasectomy desire for future children: results from a contemporary national survey, *Fertility and Sterility*, 2013, 99(7):1880–1885, doi:10.1016/j.fertnstert.2013.02.032.
14. Martinez G, Copen CE and Abma JC, Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2006–2010, *Vital and Health Statistics*, 2011, Series 23, No. 31, https://www.cdc.gov/nchs/data/series/sr_23/sr23_031.pdf.
15. Special tabulations of data from Daniels K et al., Current contraceptive use and variation by selected characteristics among women aged 15–44: United States, 2011–2013, *National Health Statistics Reports*, 2015, No. 86, 2015.
16. Lindberg L, Santelli J and Desai S, Understanding the decline in adolescent fertility in the United States, 2007–2012, *Journal of Adolescent Health*, 2016, 59(5):577–583, doi:10.1016/j.jadohealth.2016.06.024.
17. Sundaram A et al., Contraceptive failure in the United States: estimates from the 2006–2010 National Survey of Family Growth, *Perspectives on Sexual and Reproductive Health*, 2017, 49(1):7–16, doi:10.1363/psrh.12017.
18. Guttmacher Institute, *Testimony of Guttmacher Institute Submitted to the Committee on Preventive Services for Women, Institute of Medicine, January 12, 2011*, 2011, <https://www.guttmacher.org/sites/default/files/pdfs/pubs/CPSW-testimony.pdf>.
19. Kost K and Lindberg L, Pregnancy intentions, maternal behaviors, and infant health: investigating relationships with new measures and propensity score analysis, *Demography*, 2015, 52(1):83–111, doi:10.1007/s13524-014-0359-9.
20. Sonfield A et al., *The Social and Economic Benefits of Women's Ability to Determine Whether and When to Have Children*, New York: Guttmacher Institute, 2013, <https://www.guttmacher.org/report/social-and-economic-benefits-womens-ability-determine-whether-and-when-have-children>.
21. Bearak JM and Jones RK, Did contraceptive use patterns change after the Affordable Care Act? A descriptive analysis, *Women's Health Issues*, 2017, 27(3):316–321, doi:10.1016/j.whi.2017.01.006.
22. Trussell J, Raymond EG and Cleland K, Emergency contraception: a last chance to prevent unintended pregnancy, *Contemporary Readings in Law & Social Justice*, 2014, 6(2), <https://www.ceel.com/content-files/document-124303.pdf>.
23. Daniels K, Jones J and Abma JC, Use of emergency contraception among women aged 15–44, United States, 2006–2010, *NCHS Data Brief*, Hyattsville, MD: NCHS, 2013, No. 112, <https://pdfs.semanticscholar.org/009e/9e3b48fa7e2f13cc85c554c6ff433412621.pdf>.
24. Frost JJ, Frohworth LF and Zolna MR, *Contraceptive Needs and Services, 2014 Update*, New York: Guttmacher Institute, 2016, <https://www.guttmacher.org/report/contraceptive-needs-and-services-2014-update>.
25. Frost JJ et al., Return on investment: a fuller assessment of the benefits and cost savings of the US publicly funded family planning program, *Milbank Quarterly*, 2014, 92(4):696–749, doi:10.1111/1468-0009.12080.
26. Health Resources and Services Administration, U.S. Department of Health and Human Services, Women's preventive services guidelines, 2016, <https://www.hrsa.gov/womens-guidelines-2016/index.html>.
27. Guttmacher Institute, *Insurance coverage of contraceptives, State Laws and Policies*, New York: Guttmacher Institute, 2018, <https://www.guttmacher.org/state-policy/explore/insurance-coverage-contraceptives>.
28. Over-the-counter access to oral contraceptives, Committee Opinion No. 544, American College of Obstetricians and Gynecologists, *Obstet Gynecol* 2012;120:1527–31.
29. Grindlay K, Burns B, Grossman D, Prescription requirements and over-the-counter access to oral contraceptives: a global review, *Contraception* 2013;88:91–6.
30. Grossman D, Fernandez L, Hopkins K, Amastae J, Garcia SG, Potter JE, Accuracy of self-screening for contraindications to combined oral contraceptive use, *Obstet Gynecol* 2008;112:572–8.
31. Shotorbani S, Miller L, Blough DK, Gardner J, Agreement between women's and providers' assessment of hormonal contraceptive risk factors, *Contraception* 2006;73:501–6.
32. Telemedicine Companies Providing Prescription-Only MedicationsPros, Cons, and Proposed GuidelinesHariton, Eduardo MD, MBA; Tracy, Erin E. MD, MPHObstetrics & Gynecology: November 2019 - Volume 134 - Issue 5 - p 941-945
33. <https://www.bedsider.org/features/851-how-to-get-birth-control-delivered-right-to-your-door>
- 34.